Unknown

Dataset Information

0

Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16.


ABSTRACT: BACKGROUND:More smokers report using e-cigarettes to help them quit than FDA-approved pharmacotherapy. OBJECTIVE:To assess the association of e-cigarettes with future abstinence from cigarette and tobacco use. DESIGN:Cohort study of US sample, with annual follow-up. PARTICIPANTS:US adult (ages 18+) daily cigarette smokers identified at Wave 1 (W1; 2013-14) of the PATH Study, who reported a quit attempt before W2 and completed W3 (n = 2443). EXPOSURES:Use of e-cigarettes, pharmacotherapy (including nicotine replacement therapy), or no product for last quit attempt (LQA), and current daily e-cigarette use at W2. ANALYSIS:Propensity score matching (PSM) of groups using different methods to quit. OUTCOME MEASURES:12+ months abstinence at W3 from cigarettes and from all tobacco (including e-cigarettes). 30+ days abstinence at W3 was a secondary outcome. RESULTS:Among daily smokers with an LQA, 23.5% used e-cigarettes, 19.3% used pharmacotherapy only (including NRT) and 57.2% used no product. Cigarette abstinence for 12+ months at W3 was ~10% in each group. Half of the cigarette abstainers in the e-cigarette group were using e-cigarettes at W3. Different methods to help quitting had statistically comparable 12+ month cigarette abstinence at W3 (e-cigarettes vs no product: Risk Difference (RD) = 0.01, 95% CI: -0.04 to 0.06; e-cigarettes vs pharmacotherapy: RD = 0.02, 95% CI:-0.04 to 0.09). Likewise, daily e-cigarette users at W2 did not show a cessation benefit over comparable no-e-cigarette users and this finding was robust to sensitivity analyses. Abstinence for 30+ days at W3 was also similar across products. LIMITATIONS:The frequency of e-cigarette use during the LQA was not assessed, nor was it possible to assess continuous abstinence from the LQA. CONCLUSION:Among US daily smokers who quit cigarettes in 2014-15, use of e-cigarettes in that attempt compared to approved cessation aids or no products showed similar abstinence rates 1-2 years later.

SUBMITTER: Pierce JP 

PROVIDER: S-EPMC7467279 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16.

Pierce John P JP   Benmarhnia Tarik T   Chen Ruifeng R   White Martha M   Abrams David B DB   Ambrose Bridget K BK   Blanco Carlos C   Borek Nicolette N   Choi Kelvin K   Coleman Blair B   Compton Wilson M WM   Cummings K Michael KM   Delnevo Cristine D CD   Elton-Marshall Tara T   Goniewicz Maciej L ML   Gravely Shannon S   Fong Geoffrey T GT   Hatsukami Dorothy D   Henrie James J   Kasza Karin A KA   Kealey Sheila S   Kimmel Heather L HL   Limpert Jean J   Niaura Raymond S RS   Ramôa Carolina C   Sharma Eva E   Silveira Marushka L ML   Stanton Cassandra A CA   Steinberg Michael B MB   Taylor Ethel E   Bansal-Travers Maansi M   Trinidad Dennis R DR   Gardner Lisa D LD   Hyland Andrew A   Soneji Samir S   Messer Karen K  

PloS one 20200902 9


<h4>Background</h4>More smokers report using e-cigarettes to help them quit than FDA-approved pharmacotherapy.<h4>Objective</h4>To assess the association of e-cigarettes with future abstinence from cigarette and tobacco use.<h4>Design</h4>Cohort study of US sample, with annual follow-up.<h4>Participants</h4>US adult (ages 18+) daily cigarette smokers identified at Wave 1 (W1; 2013-14) of the PATH Study, who reported a quit attempt before W2 and completed W3 (n = 2443).<h4>Exposures</h4>Use of e-  ...[more]

Similar Datasets

| S-EPMC6319257 | biostudies-literature
| S-EPMC7808959 | biostudies-literature
| S-EPMC8628650 | biostudies-literature
| S-EPMC6265120 | biostudies-literature
| S-EPMC5680153 | biostudies-literature
| S-EPMC4600667 | biostudies-literature
| S-EPMC6664091 | biostudies-literature
| S-EPMC6991985 | biostudies-literature
| S-EPMC5695489 | biostudies-literature
| S-EPMC6751520 | biostudies-literature